Cargando…

Mutation profile in Indian primary myelofibrosis patients and its clinical implications

BACKGROUND: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by abnormal proliferation of megakaryocytes, bone marrow fibrosis, and extramedullary hematopoiesis. We did mutation profile of 50 patients of PMF and tried to correlate it with initial clinical presentation...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Vinod R., Chandrakala, S., Mantri, Shruti, Patil, Rajesh, Wasekar, Nilesh, Jijina, Farah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699232/
https://www.ncbi.nlm.nih.gov/pubmed/31489296
http://dx.doi.org/10.4103/sajc.sajc_276_18
_version_ 1783444679340064768
author Patil, Vinod R.
Chandrakala, S.
Mantri, Shruti
Patil, Rajesh
Wasekar, Nilesh
Jijina, Farah
author_facet Patil, Vinod R.
Chandrakala, S.
Mantri, Shruti
Patil, Rajesh
Wasekar, Nilesh
Jijina, Farah
author_sort Patil, Vinod R.
collection PubMed
description BACKGROUND: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by abnormal proliferation of megakaryocytes, bone marrow fibrosis, and extramedullary hematopoiesis. We did mutation profile of 50 patients of PMF and tried to correlate it with initial clinical presentation of these patients. MATERIALS AND METHODS: All new and follow up patients who were diagnosed as PMF based on WHO 2016 definition of PMF were included. Mutation profile of these patients including JAK2 V617F, JAK2 exon 12, CALR and MPL mutations was done and all clinical, demographic and laboratory details were recorded. RESULTS: Total 50 patients were enrolled out of which 29 were males and 21 were females. Out of these patients, 32 (64%) were JAK2 positive, 13 (26%) were CALR positive, 1 (2%) were MPL positive and 4 (8%) were triple negative. As compared to JAK2+ve patients and triple negative group, CALR positive patients were younger, had lower total leucocyte count, larger spleen size, lower dynamic international prognostic scoring system (DIPSS) score and higher grade of fibrosis of marrow. CONCLUSION: This study depicts that incidence of JAK2 and CALR mutations in Indian PMF patients is fairly similar to that in rest of the world. CALR positive patients have better clinical parameters at presentation and have better prognosis as compared to JAK2 positive patients.
format Online
Article
Text
id pubmed-6699232
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-66992322019-09-05 Mutation profile in Indian primary myelofibrosis patients and its clinical implications Patil, Vinod R. Chandrakala, S. Mantri, Shruti Patil, Rajesh Wasekar, Nilesh Jijina, Farah South Asian J Cancer ORIGINAL ARTICLE: Hematolymphoid Malignancies BACKGROUND: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by abnormal proliferation of megakaryocytes, bone marrow fibrosis, and extramedullary hematopoiesis. We did mutation profile of 50 patients of PMF and tried to correlate it with initial clinical presentation of these patients. MATERIALS AND METHODS: All new and follow up patients who were diagnosed as PMF based on WHO 2016 definition of PMF were included. Mutation profile of these patients including JAK2 V617F, JAK2 exon 12, CALR and MPL mutations was done and all clinical, demographic and laboratory details were recorded. RESULTS: Total 50 patients were enrolled out of which 29 were males and 21 were females. Out of these patients, 32 (64%) were JAK2 positive, 13 (26%) were CALR positive, 1 (2%) were MPL positive and 4 (8%) were triple negative. As compared to JAK2+ve patients and triple negative group, CALR positive patients were younger, had lower total leucocyte count, larger spleen size, lower dynamic international prognostic scoring system (DIPSS) score and higher grade of fibrosis of marrow. CONCLUSION: This study depicts that incidence of JAK2 and CALR mutations in Indian PMF patients is fairly similar to that in rest of the world. CALR positive patients have better clinical parameters at presentation and have better prognosis as compared to JAK2 positive patients. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6699232/ /pubmed/31489296 http://dx.doi.org/10.4103/sajc.sajc_276_18 Text en Copyright: © 2019 The South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle ORIGINAL ARTICLE: Hematolymphoid Malignancies
Patil, Vinod R.
Chandrakala, S.
Mantri, Shruti
Patil, Rajesh
Wasekar, Nilesh
Jijina, Farah
Mutation profile in Indian primary myelofibrosis patients and its clinical implications
title Mutation profile in Indian primary myelofibrosis patients and its clinical implications
title_full Mutation profile in Indian primary myelofibrosis patients and its clinical implications
title_fullStr Mutation profile in Indian primary myelofibrosis patients and its clinical implications
title_full_unstemmed Mutation profile in Indian primary myelofibrosis patients and its clinical implications
title_short Mutation profile in Indian primary myelofibrosis patients and its clinical implications
title_sort mutation profile in indian primary myelofibrosis patients and its clinical implications
topic ORIGINAL ARTICLE: Hematolymphoid Malignancies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699232/
https://www.ncbi.nlm.nih.gov/pubmed/31489296
http://dx.doi.org/10.4103/sajc.sajc_276_18
work_keys_str_mv AT patilvinodr mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications
AT chandrakalas mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications
AT mantrishruti mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications
AT patilrajesh mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications
AT wasekarnilesh mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications
AT jijinafarah mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications